塞库金单抗
医学
免疫学
白细胞介素23
炎症
白细胞介素17
白细胞介素
癌症研究
细胞因子
免疫系统
作者
Mayte Suárez‐Fariñas,Lewis Tomalin,Konstantin Frank,Maria Suprun,Martin Letzkus,Nicole Hartmann,Anton Glueck,M. Milutinovic,James G. Krueger
标识
DOI:10.1016/j.jaad.2020.06.428
摘要
Introduction: The objective was to determine the effect of 52-week secukinumab treatment on clinical and transcriptomic psoriasis markers. Materials and methods Biopsies of lesional and non-lesional skin from 24 patients receiving secukinumab 300 mg subcutaneously over 52 weeks (NCT01537432) were used for immunohistochemistry and gene expression analysis. The composition of the residual-disease genomic profile (RDGP; ie, molecular scar) after successful treatment with secukinumab was determined at week 12 and week 52.
科研通智能强力驱动
Strongly Powered by AbleSci AI